Literature DB >> 8549293

Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients.

G Corti1, F Paradisi, E Giganti, G Buffini, E Tortoli, L Martelli, P Pecile, P Nicoletti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549293     DOI： 10.2165/00003495-199500492-00031

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  11 in total

1.  Resistance to ciprofloxacin.

Authors:  S T Chapman; D C Speller; D S Reeves
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

2.  Clinical resistance to long-term oral ciprofloxacin.

Authors:  S M Crook; J B Selkon; P D McLardy Smith
Journal:  Lancet       Date:  1985-06-01       Impact factor: 79.321

Review 3.  Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

4.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 6.  Worldwide clinical data on efficacy and safety of ciprofloxacin.

Authors:  P Schacht; G Arcieri; J Branolte; H Bruck; V Chyský; E Griffith; G Gruenwaldt; R Hullmann; C A Konopka; B O'Brien
Journal:  Infection       Date:  1988       Impact factor: 3.553

7.  Experience with ciprofloxacin in vitro and in vivo.

Authors:  H Giamarellou; A Efstratiou; J Tsagarakis; G Petrikkos; G K Daikos
Journal:  Arzneimittelforschung       Date:  1984

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

Review 9.  Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections.

Authors:  W E Sanders
Journal:  Rev Infect Dis       Date:  1988 May-Jun

10.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321
View more
  1 in total

1.  Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries.

Authors:  Deepali Sharma; Rahul P Patel; Syed Tabish R Zaidi; Md Moklesur Rahman Sarker; Qi Ying Lean; Long C Ming
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.